the once a day formula means rapid absorption which in turn means more GI issues. Also, the six week trial seemed to be timed perfectly to get beneficial omega 3 effect but not long enough for GI issues to get build.
First statement appears to be in conflict with the 2nd? If rapid absorption = GI issues, wouldn't the problem crop up quickly? The EPA isn't being stored in body tissues like some other drugs can do AFAIK, so why would it take 6 wks for a build up leading to GI problems? Personally, if I take something my gut/intestines do not like the reaction occurs within minutes or hours, maybe the next morning at the latest.
why else would you only do a six week trial v a twelve week one?
that's a damn good question - I don't see how you get good and accurate data in such a short period of time. Hey, where did that 6 wk trial number come from anyway? I can't find in anywhere except on this website - all I can find is variations of this:
AstraZeneca also intends to get Epanova approved as a fixed dose combination with its cardiovascular drug, Crestor, for mixed dyslipidemia patients who are at a high risk of cardiovascular events. Moreover, AstraZeneca is planning to conduct a large scale cardiovascular outcomes trial to assess Epanova in combination with statins.
News 
Market Data 
Discover 
AI
